Coagulopathy in patients with Coronavirus Disease 2019 (COVID-19): A systematic review and meta-analysis

Xiaolin Zhang¹, Xue Yang¹, Hongmei Jiao¹, Xinmin Liu¹

Author information

¹Department of Geriatrics, Peking University First Hospital, Beijing 100034, China. Xiaolin Zhang and Xue Yang contributed equally to this work.

Corresponding author: Xin-min Liu MD, Department of Geriatrics, Peking University First Hospital, Beijing 100034, China. E-mail: lxm2128@163.com, TEL: +86 10 83572126.

Acronyms and Abbreviations

ACE2	Angiotensin-Converting Enzyme 2
APTT	Activated partial thromboplastin time
ARDS	Acute respiratory distress syndrome
CAC	COVID-19 associated coagulopathy
CI	Confidence interval
COVID-19	Coronavirus disease 2019
DIC	Disseminated intravascular coagulation
FIB	Fibrinogen
LMWH	Low molecular weight heparin
MERS	Middle East Respiratory Syndrome
NOAC	New oral anticoagulant
PLT	Platelet
РТ	Prothrombin time
SARS	Severe Acute Respiratory Syndrome
SARS-CoV-2	Severe Acute Respiratory Syndrome Coronavirus 2
SD	Standard deviation
SMD	Standard mean difference

Abstract:

Patients with COVID-19 frequently manifest coagulation abnormalities and thrombotic events. In this meta-analysis, we aimed to explore the role of coagulopathy on the severity differences in patients with COVID-19. We conducted systematic literature search via Pubmed, Embase, Cochrane, WanFang Database, CNKI, and medRxiv from December 1, 2019 to May 1, 2020, to identify all original studies that reports on coagulation parameters (D-dimer, PLT, PT, APTT, and FIB) during COVID-19 infection. Thereafter, we compared the coagulation parameters between less severe and more severe cases. All Statistical analyses were performed via Stata14.0 software. A total of 3,952 confirmed COVID-19 infected patients were included from 25 studies. Patients with severe COVID-19 infection exhibited significantly higher levels of D-dimer, PT, and FIB (SMD 0.83, 95% CI: 0.70-0.97, I² 56.9%; SMD 0.39, 95% CI: 0.14-0.64, I² 77.9%; SMD 0.35, 95% CI: 0.17-0.53, I² 42.4% respectively). However, difference in PLT and APTT levels between less severe and more severe patients was not statistically significant (SMD-0.26, 95% CI: -0.56-0.05, I² 82.2%; SMD-0.14,95% CI: -0.45-0.18, I² 75.5% respectively) This meta-analysis revealed coagulopathy is associated with the severity of COVID-19. Notably, D-dimer, PT, and FIB are the dominant parameters that should be considered in evaluating coagulopathy in COVID-19 patients.

Keywords: Coronavirus, COVID-19, disease severity, coagulation, coagulopathy

Introduction

Coronavirus Disease 2019 (COVID-19) is a viral respiratory infection caused by the 2019 novel coronavirus. A total of 5,061,476 confirmed cases with 331,475 deaths have been reported globally since its outbreak on May 22, 2020 [1]. Thus, the World Health Organization declared the disease a global pandemic. COVID-19 is the third most lethal zoonotic coronavirus disease after SARS and MERS that occurred in the last two decades [2], it has however caused many deaths than SARS or MERS [3]. Due to the extremely high mortality rate of COVID-19, there is an urgent need to identify clinical features associated with its progression.

Notably, coagulopathy and thrombotic events are prominent in some COVID-19 patients. Following the previous researches in China, highly prevalent coagulopathy characterized by elevated PT, APTT, and D-dimer was reported [4]. Besides, several studies reported that elevated D-dimer levels were highly associated with in-hospital mortality [5, 6]. Other than lung injuries, recent autopsy reports from the United States confirmed that severe COVID-19 patients exhibit a hypercoagulable state evidenced by thrombotic events in the lung, kidney, and possibly in the heart and other organs [7]. However, whether coagulopathy is associated with the severity of COVID-19 and the features of coagulation dysfunction remains unclear. Therefore, we conducted a systematic review and meta-analysis by incorporating both English and Chinese published literature to explore the coagulation dysfunction on the severity of COVID-19 progression.

Results

Research selection and quality assessment

The detailed literature search steps are highlighted in the flow diagram (Figure 1). We identified 1,967 records using different search strategies in the six databases. After eliminating the duplicate records, 1,132 articles were obtained. Besides, an additional 776 articles were excluded because they were not original studies or irrelevant to our meta-analysis. Full texts of the remaining 356 articles were assessed for eligibility, out

of which 322 were eliminated for meeting the exclusion criteria. A total of 34 articles were included in the quality evaluation from which 9 were excluded due to low quality (NOS<5). Eventually, we included 25 articles (1 in Chinese and 24 in English) for analyses [9-33]. The overall quality of available literature was moderate or high with NOS scores ranging from 5-7. The quality evaluation of the 34 articles is shown in Supplementary Table 2.

Characteristics of the included studies

A total of 3,952 patients in the 25 included studies provided data describing coagulation parameters in the less severe and more severe groups. Notably, 23 studies had been conducted in China (11 from Wuhan and 12 from other cities), 1 from Mexico, and 1 from the USA. All the studies were retrospective observational studies and sample size varied from 21 to 577. The median age ranged between 46 and 60 years and the proportion of male patients ranged between 35.3% and 81.0%. Twenty studies followed clinical guidelines (including trial version 4, trial version 5, trial version 7, 6th edition guidelines, 7th edition guidelines, and WHO interim guideline) to judge on the disease severity. However, two studies considered whether patients experienced ICU care to judge the severity of the disease. The patient characteristics and demographic data for the included studies are shown in Table 1.

Coagulation parameters in less severe and more severe patients

The D-dimer, PLT, PT, APTT, and FIB were available in 25, 13, 13, 9, and 5studies respectively. We use the random-effects model due to significant heterogeneity of studies on D-dimer, PLT, PT, and APTT. Notably, D-dimer and PT were significantly higher in more severe patients than in less severe patients (SMD 0.83, 95% CI: 0.70-0.97, I² 56.9%; SMD 0.39, 95% CI: 0.14-0.64, I² 77.9% respectively). The fixed-effects model was used due to the insignificant heterogeneity of studies on FIB. The result showed that patients with more severe pneumonia exhibited significantly higher FIB compared to less severe patients (SMD 0.35,95% CI: 0.17-0.53, I² 42.4%).

However, no significant difference was observed in PLT and APTT values between severe and mild patients (SMD -0.26, 95% CI: -0.56-0.05, I2 82.2%; SMD -0.14, 95% CI:-0.45-0.18, I2 75.5% respectively). A forest plot of the coagulation parameters is shown in Figure 2 and Figure 3. Details of the meta-analysis are highlighted in Table 2.

Subgroup analysis

Further, we conducted a subgroup analysis based on location, severity criteria, and age (the median value above and below 50) to determine the sources of heterogeneity. The results for subgroup analysis are presented in Table 3. Notably, the heterogeneity was significant in the subgroup analyses. However, our subgroup analyses did not explain the observed heterogeneity of studies on D-dimer, PLT, PT, and APTT.

Sensitivity analysis and publication bias

Herein, sensitivity analysis showed that the pooled results were not sensitive to any individual study, this confirmed the robustness of the study findings. Detailed results of sensitivity analysis are shown in Supplementary Figure 1. Also, we assessed publication bias using the funnel plots and Egger's regression test. There was no significant publication bias among the levels of APTT, D-dimer, FIB, PLT, PT in our study (Egger test: P=0.236, P=0.556, P=0.289, P=0.308, P=0.534 respectively). The funnel diagram and Egger's test are described in Figure 4.

Discussion

In this work, we revealed that coagulopathy is associated with the severity of COVID-19, and it is characterized by significantly elevated levels of D-dimer, PT, and FIB in more severe cases. This review concurs with the conclusions from the previous meta-analyses on the coagulative function of COVID-19 which found that PT and D-dimer are significantly higher in more severe patients [34]. However, we observed no significant decrease in the levels of PLT in more severe COVID-19 patients. Contrarily, a previous meta-analysis that included nine studies showed an

obvious heterogeneity and may lead to unstable results [35].

Moreover, increasing levels of D-dimer and PT indicates that the fibrinolytic system is activated. The coagulation cascade is activated in viral infections as a host defense mechanism to limit the spread of pathogens. Additionally, increased production of cytokines during virus infection stimulates procoagulant reactions that highly express tissue factors, a major initiator that activates coagulation. Besides, endothelial cell activation and damage may alter the natural antithrombotic state given the tropism of the virus for ACE2 receptors [36]. The acronym COVID-19 associated coagulopathy (CAC) describes the prothrombotic properties in infected patients [37]. Although coagulopathy is reminiscent of disseminated intravascular coagulation, CAC does not cause clinical bleeding which is remarkably distinct from DIC [38]. Evidence from clinical observations shows that CAC is distinct from DIC, featured by elevated fibrinogen, and nearly the normal platelet count [38]. This observation is consistent with our findings. This can be explained by the extramedullary megakaryocytes within the microvessels that have been detected in autopsy among decedents of COVID-19 [39]. The megakaryocytes can actively produce platelets within the peripheral circulation [40].

Of note, we report the first meta-analysis that assessed the fibrinogen levels on the severity of COVID-19. Similarly, several reports showed that fibrinogen significantly increases in initial and progressive stages of virus infection. Furthermore, a recent report by Ranucci *et al* [41] indicated comprehensive coagulation analyses on ICU admission with median fibrinogen levels of 7.8 g/L and increased clot strength through thromboelastometry. During the SARS-CoV-2 infection process, a cytokine storm dominated by interleukin-6 occurs [42], this has been found majorly regulate and stimulate fibrinogen synthesis. Besides, the variation in fibrinogen levels is dependent on the infection stages encountered. Elsewhere, Tang *et al* [43] reported that fibrinogen levels decline at the late stage of COVID-19 non-survivors despite increased or normal levels on admission, this is potentially caused by sepsis-induced coagulopathy.

Despite the obscure mechanism of CAC, abnormal coagulation results including elevated D-dimer and fibrin degradation products are associated with higher COVID-19 mortality rates. Thus, monitoring the levels of coagulation parameters is immensely significant in managing COVID-19. Moreover, Zhou *et al* [5] conducted a study in 191 patients from Wuhan and found that D-dimer levels higher than 1ug/L are associated with higher in-hospital mortality. The World Health Organization [44] recently issued guidelines for managing COVID-19, whereby it suggested that great focus should be geared on coagulation dysfunction and thrombotic events.

Based on our findings, we also suggest that dynamic monitoring of coagulation parameters in hospitalized COVID-19 patients is necessary for predicting COVID-19 progression that is associated with unfavorable outcome and early thrombotic events. Moreover, futures studies should determine whether early anticoagulation features such as low molecular weight heparin (LMWH), warfarin, or new oral anticoagulant (NOAC) are beneficial in patients with significantly elevated coagulation parameters.

Besides, our meta-analysis has a few limitations. First, there was obvious heterogeneity among studies regarding definitions of the COVID-19 severity, and either subgroup or sensitivity analyses could not identify the heterogeneity source. Some selected studies did not report using mean and standard deviation, however, they gave estimates by median and quartile which may lead to deviation and effect heterogeneity. We excluded the low-quality studies to maintain the reliability of the conclusion. Second, this meta-analysis was conducted for studies that failed to describe all relevant characteristics of individual patients and it was difficult to adjust on the potentially confounding factors such as comorbidity and treatment (including use of anticoagulation or glucocorticoid). Finally, we included retrospective studies in the meta-analysis and there are risks of bias in the data collected.

In conclusion, coagulopathy is associated with the severity of COVID-19. The D-dimer, PT, and FIB are dominant parameters for evaluating coagulopathy in COVID-19. COVID-19 associated coagulopathy has different features from DIC, therefore, it is necessary to closely monitor the dynamics of coagulation parameters.

Methods

Search strategy

The protocol for this systematic review and meta-analysis has been registered on the International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLSY) as INPLASY2020500049 (https://inplasy.com/). The reports included in the systematic review follows the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines (the checklist is shown in Supplementary Table 1). The literature reports were written in English and Chinese. We conducted a literature search on the electronic databases including Pubmed, Embase, Cochrane, WanFang Database, CNKI and medRxiv for reports published from December 1, 2019 to May 1, 2020 using a combination of the following keywords: "COVID-19" or "2019 novel coronavirus infection" or "SARS-CoV-2" and" characteristics" or" coagulopathy" or "coagulation". Besides, we screened and conducted a manual search of the references listed in each article to obtain comprehensive results. The search was done independently by two authors (Xiaolin Zhang and Xue Yang). A third investigator (Hongmei Jiao) came in to resolve any contradicting search results.

Inclusion and exclusion criteria

The inclusion criteria were as follows: (1) Original studies focused on clinical characteristics of patients with COVID-19 including observational study, case-control studies, cohort studies, and randomized control studies; (2) patients were categorized into less and more severe groups; (3) the coagulation parameters between groups were described. Exclusion criteria were as follows: (1) Non-original studies including commentaries, editorials, case reports, letters, meta-analysis, guidelines, and family-based studies; (2) same patients are enrolled in different articles; (3) patients in studies are below 18 years old.

Data extraction and quality assessment

Two investigators (Xiaolin Zhang and Xue Yang) independently extracted data and

evaluated the quality of literature reports. Contradicting decisions from the two authors were resolved by a third investigator (Hongmei Jiao) or through consensus. Data items extracted from each study included the study characteristics, demographic information, and outcomes of interest. We used the Newcastle-Ottawa scale (NOS) which included patient selection, study comparability, and three components of outcomes assessment to evaluate the quality of the original study. Low-quality articles (NOS<5) were excluded from this meta-analysis.

Data analysis

All statistical analyses were performed via Stata 14.0 (Stata, College Station, TX, USA). For continuous variables, we calculated the standard mean difference (SMD) and the 95%CI. Heterogeneity among the studies was assessed using the Chi-squared and I² tests. For studies that only reported median and range, CI or interquartile range, we estimated means and SDs as described by Wan [8]. A random-effects model was used when either P<0.05 or I²>50% defined significant heterogeneity across the articles. Otherwise, we used the fixed-effects model. A p-value of less than 0.05 was considered significant statistically. Further, a sensitivity analysis was conducted to evaluate the stability of the results and determine the effect of individual study on pooled results. Evidence of publication bias was examined using Egger's regression test for funnel asymmetry in addition to the visual inspection of funnel plots.

ACKNOWLEDGMENT

None.

CONFLICTS OF INTEREST

Xiaolin Zhang, Xue Yang, Hongmei Jiao, Xinmin Liu declare that they have no competing interests.

AUTHOR CONTRIBUTIONS

Study conception and design: Xiaolin Zhang. Data acquisition: Xiaolin Zhang, Xue Yang. Statistical analysis: Xiaolin Zhang. Interpretation of the data: Xiaolin Zhang, Xue Yang. Drafting of the manuscript: all authors. Critical revision the manuscript for important intellectual content: all authors. Final approval of the manuscript: all authors.

Funding information This work was supported by the Scientific Research Seed Fund of Peking University First Hospital (Grant No. 2018SF058).

References

- 1. World Health Organization 2020 [https://who.sprinklr.com/]
- TG K, D E, CS G, SR Z, T P, S E, S T, C U, JA C, W L *et al.* A novel coronavirus associated with severe acute respiratory syndrome. *The New England journal of medicine* 2003, 348(20):1953-1966.
- 3. Y L, AA G, A W-S, J R: The reproductive number of COVID-19 is higher compared to SARS coronavirus. *Journal of travel medicine* 2020, **27**(2).
- N C, M Z, X D, J Q, F G, Y H, Y Q, J W, Y L, Y W *et al.* Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet (London, England)* 2020, 395(10223):507-513.
- F Z, T Y, R D, G F, Y L, Z L, J X, Y W, B S, X G *et al.* Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet (London, England)* 2020, 395(10229):1054-1062.
- C W, X C, Y C, J X, X Z, S X, H H, L Z, X Z, C D *et al*. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA internal medicine* 2020.

- 7. LM B, DA W, B Z, B A, M M, L L, N R, G O, MT E, DO T *et al.* The emerging spectrum of cardiopulmonary pathology of the coronavirus disease 2019 (COVID-19): Report of 3 autopsies from Houston, Texas, and review of autopsy findings from other United States cities. *Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology* 2020, 48:107233.
- 8. X W, W W, J L, T T: Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. *BMC medical research methodology* 2014, 14:135.
- Bai X, Fang C, Zhou Y, Bai S, Liu Z, Chen Q, Xu Y, Xia T, Gong S, Xie X *et al*.
 Predicting COVID-19 malignant progression with AI techniques. *medRxiv* 2020:2020.2003.2020.20037325.
- Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, Wang T, Zhang X, Chen H, Yu H *et al*. Clinical and immunological features of severe and moderate coronavirus disease
 2019. *J Clin Invest* 2020, 130(5):2620-2629.
- 11. Chen X, Zheng F, Qing Y, Ding S, Yang D, Lei C, Yin Z, Zhou X, Jiang D, Zuo Q *et al*. Epidemiological and clinical features of 291 cases with coronavirus disease 2019 in areas adjacent to Hubei, China: a double-center observational study. *medRxiv* 2020:2020.2003.2003.20030353.
- Cheng Y, Zhou Y, Zhu M, Zha L, Lu Z, Ding Z, Yang J, Yang G: Eosinopenia Phenotype in Patients with Coronavirus Disease 2019: A Multi-center Retrospective Study from Anhui, China. *medRxiv*2020:2020.2004.2022.20071050.
- 13. H H, L Y, R L, F L, KL W, J L, XH L, CL Z: Prominent changes in blood coagulation of

patients with SARS-CoV-2 infection. Clinical chemistry and laboratory medicine 2020.

- 14. Jiang X, Tao J, Wu H, Wang Y, Zhao W, Zhou M, Huang J, You Q, Meng H, Zhu F *et al*. Clinical features and management of severe COVID-19: A retrospective study in Wuxi, Jiangsu Province, China. *medRxiv*2020:2020.2004.2010.20060335.
- 15. lei I, Jian-ya G: Clinical characteristics of 51 patients discharged from hospital with COVID-19 in Chongqing , China. *medRxiv*2020:2020.2002.2020.20025536.
- Li Dan LY, Huang Peng,Guo wenlong,Wu shuanghua,Zhou Qing,Fu jingli: Clinical characteristics of 80 patients with COVID-19 in Zhuzhou City. *Chin J Infect Control* 2020, 19(3):227-234.
- Liu Y, Sun W, Li J, Chen L, Wang Y, Zhang L, Yu L: Clinical features and progression of acute respiratory distress syndrome in coronavirus disease 2019. *medRxiv* 2020:2020.2002.2017.20024166.
- Liu W, Tao ZW, Wang L, Yuan ML, Liu K, Zhou L, Wei S, Deng Y, Liu J, Liu HG *et al*.
 Analysis of factors associated with disease outcomes in hospitalized patients with
 2019 novel coronavirus disease. *Chin Med J (Engl)* 2020, 133(9):1032-1038.
- 19. Lu H, Ai J, Shen Y, Li Y, Li T, Zhou X, Zhang H, Zhang Q, Ling Y, Wang S *et at*. A descriptive study of the impact of diseases control and prevention on the epidemics dynamics and clinical features of SARS-CoV-2 outbreak in Shanghai, lessons learned for metropolis epidemics prevention. *medRxiv*2020:2020.2002.2019.20025031.
- 20. Lu J, Hu S, Fan R, Liu Z, Yin X, Wang Q, Lv Q, Cai Z, Li H, Hu Y *et al*. ACP risk grade: a simple mortality index for patients with confirmed or suspected severe acute respiratory syndrome coronavirus 2 disease (COVID-19) during the early stage of

outbreak in Wuhan, China. medRxiv2020:2020.2002.2020.20025510.

- 21. Luo X, Xia H, Yang W, Wang B, Guo T, Xiong J, Jiang Z, Liu Y, Yan X, Zhou W *et al.* Characteristics of patients with COVID-19 during epidemic ongoing outbreak in Wuhan, China. *medRxiv*2020:2020.2003.2019.20033175.
- Pei G, Zhang Z, Peng J, Liu L, Zhang C, Yu C, Ma Z, Huang Y, Liu W, Yao Y *et al.* Renal Involvement and Early Prognosis in Patients with COVID-19 Pneumonia. *J Am Soc Nephrol* 2020.
- 23. Pereira MR, Mohan S, Cohen DJ, Husain SA, Dube GK, Ratner LE, Arcasoy S, Aversa MM, Benvenuto LJ, Dadhania DM *et al*. **COVID-19 in solid organ transplant recipients: Initial report from the US epicenter**. *Am J Transplant* 2020.
- Shi P, Ren G, Yang J, Li Z, Deng S, Li M, Wang S, Xu X, Chen F, Li Y *et al.* Clinical characteristics of imported and second-generation COVID-19 cases outside Wuhan, China: A multicenter retrospective study. *medRxiv*2020:2020.2004.2019.20071472.
- 25. Valente-Acosta B, Hoyo-Ulloa I, Espinosa-Aguilar L, Mendoza-Aguilar R, Garcia-Guerrero J, Ontanon-Zurita D, Gomez-Gomez B, Fueyo-Rodriguez O, Vera-Zertuche JM, Anzola-Arias R *et al.* COVID-19 severe pneumonia in Mexico City First experience in a Mexican hospital. *medRxiv* 2020:2020.2004.2026.20080796.
- 26. Wang D, Wang J, Jiang Q, Yang J, Li J, Gao C, Jiang H, Ge L, Liu Y: No Clear Benefit to the Use of Corticosteroid as Treatment in Adult Patients with Coronavirus Disease 2019 : A Retrospective Cohort Study. *medRxiv*2020:2020.2004.2021.20066258.
- 27. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C *et al.* Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in

> Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med 2020.

- 28. H X, J Z, N L, S L, Q X, H Z: Clinical characteristics of non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: A retrospective study. *Liver international : offici`al journal of the International Association for the Study of the Liver* 2020.
- Yan S, Song X, Lin F, Zhu H, Wang X, Li M, Ruan J, Lin C, Liu X, Wu Q *et al*. Clinical Characteristics of Coronavirus Disease 2019 in Hainan, China. *medRxiv* 2020:2020.2003.2019.20038539.
- 30. zhang h, wang x, fu z, luo m, zhang z, zhang k, he y, wan d, zhang l, wang j *et al*.
 Potential Factors for Prediction of Disease Severity of COVID-19 Patients. *medRxiv* 2020:2020.2003.2020.20039818.
- 31. JJ Z, X D, YY C, YD Y, YB Y, YQ Y, CA A, YD G: Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. *Allergy* 2020.
- 32. Y Z, H X, M Y, Y Z, H C, R L, Q L, N Z, D W: Epidemiological characteristics and clinical features of 32 critical and 67 noncritical cases of COVID-19 in Chengdu. *Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology* 2020, 127:104366.
- Zhou Y, Han T, Chen J, Hou C, Hua L, He S, Guo Y, Zhang S, Wang Y, Yuan J *et al.* Clinical and Autoimmune Characteristics of Severe and Critical Cases of COVID-19.
 Clin Transl Sci 2020.
- 34. Xiong M, Liang X, Wei YD: Changes in blood coagulation in patients with severe

coronavirus disease 2019 (COVID-19): a meta-analysis. Br J Haematol 2020.

- 35. Lippi G, Plebani M, Henry BM: Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. *Clin Chim Acta* 2020, **506**:145-148.
- 36. J T, N T, S G, A F, M C, M L, C C, T I: **ISTH interim guidance on recognition and** management of coagulopathy in COVID-19. *Journal of thrombosis and haemostasis : JTH* 2020, **18**(5):1023-1026.
- 37. RC B: COVID-19 update: Covid-19-associated coagulopathy. *Journal of thrombosis* and thrombolysis 2020.
- JM C, JH L: COVID-19 and its implications for thrombosis and anticoagulation. Blood
 2020.
- 39. Fox SE AA, Harbert JL, Li G, Brown JQ, Vander Heide RS: **Pulmonary and cardiac** pathology in Covid-19: the frst autopsy series from New Orleans. . *medRxiv* 2020.
- 40. E L, G O-M, A C, B M, F L, DM S, EE T, MB H, T D, SR C *et at*. The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors. *Nature* 2017, 544(7648):105-109.
- 41. M R, A B, U DD, E B, M DP, M R, M F, G A, L M: The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. *Journal of thrombosis and haemostasis : JTH* 2020.
- 42. M B, M K, SA L, F S, M D: Cytokine storm in COVID-19 and parthenolide: preclinical evidence. *Phytotherapy research : PTR* 2020.
- 43. N T, D L, X W, Z S: Abnormal coagulation parameters are associated with poor

prognosis in patients with novel coronavirus pneumonia. Journal of thrombosis and

haemostasis : JTH 2020, 18(4):844-847.

44. Organization WH: Clinical management of COVID-19 : interim guidance. In.; 2020.

Figure legends

Figure 1. Systematic searches of the literature.

Figure 2.

Forest plot of the association between D-dimer, PLT, PT, APTT in patients with COVID-19 stratified by disease severity.

Figure 3.

Forest plot of the association between FIB in patients with COVID-19 stratified by disease severity.

Figure 4.


Funnel plot and Egger's test evaluating the publication bias of (A) APTT, (B) D-dimer, (C) FIB, (D) PLT, (E) PT.


Figure 1. Literature search and selection process.

```
Records identified through database searching
(n = 1967)
Pubmed= 580, Embase= 424, Cochrane= 25,
MedRxiv= 178, Wanfang= 579, CNKI= 181
```

Records after duplicates removed

Studies were excluded: Case reports






	More	Less		%
Study	severe	severe	SMD (95% CI)	Weight
D-dimer				
Bai et al	1.40±3.65	0.61±1.95	0.29 (-0.06, 0.63)	5.26
Chen G et al	7.78±15.35	0.33±0.09	0.67 (-0.21, 1.55)	1.78
Chen Xu et al	0.45±0.24	0.29±0.19	0.80 (0.49, 1.11)	5.66
Cheng et al	1.05±0.81	0.48±0.21	1.65 (0.85, 2.46)	2.06
Han et al	20.04±32.39	9.21±22.95	• 0.45 (-0.21, 1.11)	2.73
Jiang et al	0.71±0.80	0.34±0.21	1.06 (0.28, 1.83)	2.17
Lei et al	0.78±1.03	0.31±0.21	1.14 (0.32, 1.97)	1.96
Li et al	0.77±0.55	0.27±0.20	1.63 (1.04, 2.23)	3.12
Liu Y et al	1.11±1.09	0.43±0.30	0.86 (0.47, 1.25)	4.79
Liu W et al	2.74±5.62	0.56±0.65	1.03 (0.37, 1.68)	2.73
Lu H et al	1.66±2.38	0.46±0.32	1.62 (1.17, 2.08)	4.17
Lu J et al	1.06±1.50	0.34±0.44	0.89 (0.66, 1.12)	6.58
Luo et al	3.16±5.18	0.49±0.45	0.72 (0.52, 0.92)	6.91
Pei et al	2.67±4.00	0.78±0.44	1.13 (0.83, 1.43)	5.80
Pereira et al	2.34±2.20	1.23±0.99	0.70 (0.20, 1.20)	3.80
Shi et al	0.67±0.69	0.50±0.30	0.36 (0.00, 0.72)	5.14
Valente et al	1.02±0.36	0.80±0.45	0.51 (-0.30, 1.32)	2.05
Wang D et al	1.51±1.83	0.36±0.23	0.90 (0.52, 1.29)	4.88
Wu C et al	2.40±3.70	0.59±0.93	0.73 (0.44, 1.02)	5.92
Xie et al	1.20±1.51	0.78±0.79	0.38 (-0.08, 0.85)	4.10
Yan et al	1.20±1.78	0.33±0.22	1.04 (0.65, 1.42)	4.87
Zhang H et al	3.30±5.16	0.35±0.24	1.01 (0.34, 1.69)	2.64
Zhang JJ et al	1.03±1.67	0.20±0.15	0.78 (0.42, 1.13)	5.21
Zheng et al	2.65±3.93	0.78±0.76	0.79 (0.35, 1.23)	4.31
Zhou Y et al	0.28±0.11	0.29±0.11	-0.09 (-1.13, 0.95)	1.36
Subtotal (I-squ	ared = 56.9%, p	= 0.000)	0.83 (0.70, 0.97)	100.00

. PLT

Chen G et al	158.65±42.84	172.31±39.30
Chen Xu et al	168.80±61.98	227.41±115.64
Cheng et al	189.83±10.63	169.96±21.82
Jiang et al	175.00±22.66	186.00±18.63
Lei et al	165.49±100.12	189.16±75.10
Li et al	179.18±86.40	195.38±40.99
Liu W et al	143.90±64.81	173.20±55.37
Lu H et al	163.54±70.53	179.46±57.42
Luo et al	186.67±36.50	206.67±35.82
Pereira et al	175.00±29.07	177.67±27.01
Shi et al	186.33±28.42	170.00±28.19
Yan et al	159.67±30.11	201.83±33.69
Zhang H et al	194.73±118.62	179.63±75.63
Subtotal (I-squ	ared = 82.2%, p	= 0.000)

. PT

Bai et al	13.88±2.88	13.18±1.14			- -			0.01 (-0.34, 0.35)	8.88
Chen G et al	14.15±0.85	13.29±0.77				۲		1.06 (0.14, 1.98)	4.41
Han et al	12.80±0.87	12.39±0.99			•			0.42 (-0.24, 1.08)	6.18
Jiang et al	12.85±1.07	13.27±0.31	-	•	-			-0.87 (-1.63, -0.10)	5.37
Li et al	15.01±1.18	13.58±0.94					<u> </u>	1.44 (0.86, 2.02)	6.81
Lu H et al	13.50±0.95	13.37±0.60		4	•	-		0.20 (-0.23, 0.64)	8.08
Lu J et al	14.08±1.58	14.01±1.12						0.06 (-0.17, 0.28)	9.84
Pei et al	14.36±0.83	14.06±1.01			•			0.31 (0.02, 0.59)	9.36
Shi et al	12.30±2.37	11.98±2.04			•			0.15 (-0.21, 0.51)	8.78
Wu C et al	11.75±1.02	10.74±1.05						0.97 (0.68, 1.27)	9.29
Yan et al	11.88±1.16	11.60±0.90			-	-8		0.29 (-0.08, 0.66)	8.67
Zhang H et al	10.61±0.58	10.40±0.47		2	-			0.41 (-0.23, 1.06)	6.29
Zheng et al	13.49±0.96	12.91±0.63				•		0.77 (0.33, 1.21)	8.04
Subtotal (I-squ	ared = 79.4%,	p = 0.000)			$\langle \rangle$			0.39 (0.14, 0.64)	100.00
iv preprint doi: https://doi.org/10.1101/2020.07.15.20154 ch was not certified by peer review) is the author/funder, All rights reserved. No	138; this version posted July 16, 2020. T who has granted medRxiv a license to d	The copyright holder for this preprint display the preprint in perpetuity.							
Áll rights reserved. No	reuse allowed without permission.								
Bai et al	34.66±5.83	34.40±4.45		_	•			0.05 (-0.29, 0.40)	13.56
Chen G et al	34.84±5.34	44.81±4.30	-		T			-2.05 (-3.12, -0.97)	5.61
Han et al	29.41±1.68	28.96±3.03		3 	•	_		0.15 (-0.50, 0.81)	9.52
Jiang et al	37.26±4.38	39.37±4.66		•				-0.46 (-1.21, 0.30)	8.40
Lu H et al	42.73±9.91	39.19±4.25			<u> </u>	•		0.72 (0.28, 1.16)	12.31
Shi et al	32.85±8.04	31.83±5.88			-			0.15 (-0.20, 0.51)	13.42
Wu C et al	27.96±9.39	29.36±5.48		_	•			-0.19 (-0.47, 0.09)	14.37
Yan et al	28.65±5.02	29.52±4.57			•			-0.19 (-0.56, 0.18)	13.27
Zhang H et al				•				-0.68 (-1.33, -0.02)	9.54
Subtotal (I-squ				<				-0.14 (-0.45, 0.18)	100.00
OTE: Weights are	from random	effects analysis	S						
								2	
		-3	-2	-1	0		2	3	



-0.33 (-1.19, 0.53)	5.65
-0.54 (-0.85, -0.23)	9.34
0.96 (0.19, 1.72)	6.25
-0.57 (-1.33, 0.18)	6.31
-0.30 (-1.10, 0.50)	6.04
-0.30 (-0.84, 0.24)	7.82
-0.52 (-1.16, 0.13)	7.08
-0.27 (-0.71, 0.17)	8.52
-0.55 (-0.75, -0.35)	9.89
-0.10 (-0.58, 0.39)	8.18
0.58 (0.21, 0.94)	9.01
-1.28 (-1.67, -0.89)	8.81
0.17 (-0.47, 0.80)	7.10
-0.26 (-0.56, 0.05)	100.00

	Bai et al	13.88±2.88	13.18±1.14	6			•			0.01 (-0.34, 0.35)	8.88
	Chen G et al	14.15±0.85	13.29±0.77					•		1.06 (0.14, 1.98)	4.41
	Han et al	12.80±0.87	12.39±0.99	1		-				0.42 (-0.24, 1.08)	6.18
	Jiang et al	12.85±1.07	13.27±0.31			•	-			-0.87 (-1.63, -0.10)	5.37
	Li et al	15.01±1.18	13.58±0.94					•	 	1.44 (0.86, 2.02)	6.81
	Lu H et al	13.50±0.95	13.37±0.60	Fi		-	•	-		0.20 (-0.23, 0.64)	8.08
	Lu J et al	14.08±1.58	14.01±1.12							0.06 (-0.17, 0.28)	9.84
	Pei et al	14.36±0.83	14.06±1.01				•			0.31 (0.02, 0.59)	9.36
	Shi et al	12.30±2.37	11.98±2.04	1		-	•			0.15 (-0.21, 0.51)	8.78
	Wu C et al	11.75±1.02	10.74±1.05	2						0.97 (0.68, 1.27)	9.29
	Yan et al	11.88±1.16	11.60±0.90				•	-		0.29 (-0.08, 0.66)	8.67
	Zhang H et al	10.61±0.58	10.40±0.47				•			0.41 (-0.23, 1.06)	6.29
	Zheng et al	13.49±0.96	12.91±0.63	l.				•		0.77 (0.33, 1.21)	8.04
	Subtotal (I-squ	ared = 79.4%,	p = 0.000)				\diamond			0.39 (0.14, 0.64)	100.00
medRxiv preprint (which was not	doi: https://doi.org/10.1101/2020.07.15.201541 t certtfied by peer review) is the author/funder, v All rights reserved. No r	38; this version posted July 16, 2020. The version posted July 16, 2020. The version of the v	e copyright holder for this preprint splay the preprint in perpetuity.	t							
	All rights reserved. No r	euse allowed without permission.									
	Bai et al	34.66±5.83	34.40±4.45				•			0.05 (-0.29, 0.40)	13.56
	Chen G et al	34.84±5.34	44.81±4.30	← ●						-2.05 (-3.12, -0.97)	5.61
	Han et al	29.41±1.68	28.96±3.03	8		<u>.</u>	•	()		0.15 (-0.50, 0.81)	9.52
	Jiang et al	37.26±4.38	39.37±4.66	1	-	•				-0.46 (-1.21, 0.30)	8.40
	Lu H et al	42.73±9.91	39.19±4.25	3			55	•		0.72 (0.28, 1.16)	12.31
	Shi et al	32.85±8.04	31.83±5.88				•			0.15 (-0.20, 0.51)	13.42
	Wu C et al	27.96±9.39	29.36±5.48							-0.19 (-0.47, 0.09)	14.37
	Yan et al	28.65±5.02	29.52±4.57							-0.19 (-0.56, 0.18)	13.27
	Zhang H et al	25.13±2.97	26.93±2.49	6	-	•	-			-0.68 (-1.33, -0.02)	9.54
	Subtotal (I-squ	ared = 75.7%,	p = 0.000)			<	\rightarrow			-0.14 (-0.45, 0.18)	100.00
NOT	E: Weights are f	rom random e	effects analy	lysis							
					-		_		50 (š		
			-3	3	-2	-1	0	1	2	3	
			-0	0	-2		0		2	0	

Study

ID

FIB

Chen Xu et al

Han et al

medRxiv preprint doi: https://doi.org/10.1101/2020.07.15.20154138; this version posted July 16, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Liu Y et al


Shi et al

Zhang H et al

Overall (I-squared = 42.4%, p = 0.139)

Note: Weights are from fixed effects analysis


SMD (95% CI)



%

Weight

)	36.03
)	7.72
	22.37
)	26.17
	7.71
	100.00






Table1.Main characteristics of the included studies in meta-analysis.

Author	Period	Country	Locatio	Language	Study design	Sample	Age [(mean ± SD),	Male, number (%)	Severe definition	Outcome group, n (%)	Quality	Referen
			n				or median]				score	се
Bai et	2020.1.3-2	China	Wuhan	English	Retrospective	133	52.82±12.59	66 (49.6%)	guidelines	Less severe 79 (59.4%)	6	9
al	020.2.13				study					More severe 54 (40.6%)		
Chen G	2019.12-2	China	Wuhan	English	Retrospective	21	56.0 (50.0, 65.0)	17 (81.0%)	guidelines	Less severe 10 (47.6%)	6	10
et al	020.1.27				study					More severe 11 (52.4%)		
Chen	2020.1.23-	China	Hunan	English	Retrospective	291	46.0(34.0, 59.0)	145 (49.8%)	guidelines	Mild 29 (10%)	5	11
Xu et al	2020.2.14				study					Moderate 212 (72.8%)		
										Severe/critical 50 (17.2%)		
Cheng	2020.1.23-	China	Anhui	English	Retrospective	59	39.0 (30.0, 54.0)	32 (54.2%)	guidelines	Mild 5 (8.5%)	6	12
et al	2020.3.10				Study					Moderate 46 (78%)		
										Severe 8 (13.5%)		
Han et	2020.1.31-	China	Wuhan	English	Retrospective	94	NA	48 (51%)	guidelines	Ordinary 49 (52.1%)	5	13
al	2020.2.10				Study					Severe 35 (37.2%)		
										Critical 10 (10.7%)		
Jiang et	2020.1.23-	China	Wuxi	English	Retrospective	55	45.0 (27.0,60.0)	27 (49.1%)	guidelines	Non-severe 47 (85.5%)	6	14
al	2020.2.16				study					Severe 8 (14.5%)		
Lei et al	2020.1.20-	China	Chongqi	English	Retrospective	51	45.0 (34.0, 51.0)	32(62.7%)	guidelines	Non-severe 44 (86.3%)	5	15
	2020.2.3		ng		study					Severe 7 (13.7%)		
Li et al	2020.1.20-	China	Hunan	Chinese	Retrospective	80	47.5 (3-90)	40 (50%)	guidelines	Non-severe 63 (78.8%)	5	16
	2020.2.27				study					Severe 17 (21.2%)		
Liu Y et	2020.1.2-2	China	Wuhan	English	Retrospective	109	55 (43-66)	59 (54.1)	ARDS	Non-ARDS (n = 56)	6	17

al	020.2.1				study					ARDS (n = 53)		
Liu W	2020.12.3	China	Wuhan	English	Retrospective	78	38 (33, 57)	39 (50.0)	guidelines	Improvement/stabilization	6	18
et al	0-2020.1.1				study					67 (85.9%)		
	5									Progression 11(14.1%)		
Lu H et	2020.1.20-	China	Shangh	English	Retrospective,	265	NA	NA	guidelines	Mild-moderate 243 (91.7%	5)5	19
al	2020.2.9		ai		cohort study					Severe-critically 22 (8.3%))	
Lu J et	2020.1.21-	China	Wuhan	English	Retrospective	577	55 (39, 66)	254 (44.0)	guidelines	Mild 338 (77.2%)	6	20
al	2020.2.5				cohort study					Severe 100 (22.8%)		
Luo et	2020.1.30-	China	Wuhan	English	Retrospective	403	56 (39, 68)	193 (47.9%)	guidelines	Ordinary 198 (49.1%)	6	21
al	2020.2.25				cohort study					Severe or critical 205		
										(50.9%)		
Pei et al	2020.1.28-	China	Wuhan	English	Retrospective	333	56.36±13.4	182(54.7%)	guidelines	Moderate 144 (43.2%)	6	22
	2020.2.9				cohort study					Severe 133 (39.9%)		
										Critically III 56 (16.8%)		
Pereira	2020.3.13-	American	New	English	Retrospective	90	57 (46, 68)	53 (59%)	ICU	Mild/moderate disease 63	5	23
et al	2020.4.3		York		cohort study					(70%)		
										Severe disease 27 (30%)		
Shi et	2020.1.23-	China	Shanxi	English	Retrospective	134	46(34, 58)	65(48.5%)	guidelines	Non-severe 88 (65.7%)	6	24
al	2020.3.7				cohort study					Severe 46 (34.2%)		
Valente	2020.3.13-	Mexico	Mexico	English	Descriptive	33	60.6±12.68	23 (69.7%)	guidelines	Severe Pneumonia 25	5	25
et al	2020.4.13				case series					(75.8%)		
					report					Critical Pneumonia 8		
										(24.2%)		

Wang D	2020.1.18-	China	Wuhan	English	Descriptive	115	59 (40-67)	58 (50.4%)	guidelines	Noncritical 60 (52.2%)	6	26
et al	2020.2.28				case series					Critical 55 (47.8%)		
					report							
Wu C et	2019.12.2	China	Wuhan	English	Retrospective	201	51 (43-60)	128 (63.7%)	ARDS	Without ARDS 117	6	27
al	5-2020.1.2				cohort study					(58.2%)		
	6									With ARDS 84 (41.8%)		
Xie et al	2020.2.2-2	China	Wuhan	English	Retrospective	79	60.0 (48.0-66.0)	44 (55.7%)	guidelines	Moderate 51 (64.6%)	5	28
	020.2.23				cohort study					Severe 28 (35.4%)		
Yan et	2020.1.22-	China	Hainan	English	Retrospective	168	51 (36-62)	81 (48.2%)	guidelines	Non-severe132 (78.6%)	6	29
al	2020.3.14				cohort study					Severe 36 (21.4%)		
Zhang	2020.1.11-	China	Chongqi	English	Retrospective	43	NA	22 (51.2%)	guidelines	Mild 29 (67.4%)	5	30
H et al	2020.1.28		ng		cohort study					Severe 14 (32.6%)		
Zhang	2020.1.16-	China	Wuhan	English	Retrospective	140	57 (25-87)	71 (50.7%)	guidelines	Non-severe 82 (58.6%)	7	31
JJ et al	2020.2.3				cohort study					Severe 58 (41.4%)		
Zheng	2020.1.16-	China	Chengd	English	Retrospective	99	49.40±18.45	51 (51.5%)	guidelines	Noncritical 67 (67.7%)	5	32
et al	2020.2.20		u		cohort study					Critical 32 (32.3%)		
Zhou Y	2020.1.28-	China	Nanjing	English	Retrospective	21	NA	6(35.3%)	guidelines	Non-aggravation 12 (70.6	6%)6	33Aggravatio
et al	2020.3.2				cohort study					Aggravation 5 (29.4%)		
	1	1	1	l	1	1	1	1			1	

			Test o	of associatio		Heterogeneity				
Groups	Studies	SMD	95%CI	p value	Model	Ζ	Chi-squared	p value	I2(%)	
D-dimer	25	0.83	0.70,0.97	0.000	RE	12.27	55.63	0.000	56.9	
PLT	13	-0.26	-0.56,0.05	0.096	RE	1.66	67.27	0.000	82.2	
PT	13	0.39	0.14,0.64	0.002	RE	3.04	58.16	0.000	77.9	
APTT	9	-0.14	-0.45,0.18	0.384	RE	0.87	32.89	0.000	75.5	
FIB	5	0.35	0.17,0.53	0.000	FE	3.75	6.94	0.139	42.4	

Table 2.Summary of the meta-analysis results

RE, random effects

FE, fixed effects

SMD, standardized mean difference

CI, confidence interval

Table 3. Results of subgroup meta-analyses.

			No.of studies	SMD (95%CI)	P-value	Heterogeneity	
						I ²	P value
D-dimer	Criteria	Guidelines	22	0.85(0.69,1.00)	0.000	61.8	0.000
		ARDS	2	0.77(0.54,1.01)	0.000	0	0.588
		ICU care	1	0.70(0.20,1.20)	0.006	Null	Null
	Location	Wuhan	12	0.76(0.62,0.89)	0.000	42.1	0.061
		Other cities in China	11	1.01(0.72,1.30)	0.000	69	0.000
		Other countries	2	0.65(0.22,1.07)	0.003	0	0.692
	Age	≥50	13	0.72(0.57,0.86)	0.031	48.2	0.026
		<50	9	0.97(0.76,1.17)	0.030	33.8	0.147
PLT	Criteria	Guidelines	12	-0.27(0.60,0.06)	0.104	83.3	0.000
		ICU care	1	-0.10(-0.59,0.39)	0.699	Null	Null
	Location	Wuhan	3	-0.54(-0.73,-0.35)	0.000	0	0.884
		Other cities in China	9	-0.19(-0.65,0.26)	0.407	87	0.000
		Other countries	1	-0.10(-0.58,0.39)	0.699	Null	Null
	Age	≥50	5	-0.26(-0.65,0.14)	0.281	92.1	0.000
		<50	6	-0.34(-0.96 , 0.28)	0.199	62.3	0.021
РТ	Criteria	Guidelines	12	0.36(0.13,0.59)	0.002	69.6	0.000

		ARDS	1	0.91(0.68,1.27)	0.000	Null	Null
	Location	Wuhan	6	0.47(0.13,0.81)	0.070	80.7	0.000
		Other cities in China	7	0.37(-0.03,0.76)	0.068	78.8	0.000
	Age	≥50	6	0.47(0.17,0.76)	0.002	72.9	0.002
		<50	5	0.39(-0.22,1.00)	0.214	87.7	0.000
APTT	Criteria	Guidelines	8	-0.15(0.53,0.23)	0.432	77.8	0.000
		ARDS	1	-0.19(-0.47,0.09)	0.185	Null	Null
	Location	Wuhan	4	'-0.30(-0.82 , 0.22)	0.259	78.8	0.003
		Other cities in China	5	-0.04(-0.48,0.40)	0.862	76.7	0.002
	Age	≥50	6	-0.15(-0.47,0.16)	0.347	69.5	0.097
		<50	1	·-0.46(-1.12,0.30)	0.236	Null	Null